The U.S. Food and Drug Administration has issued an alert warning health care professionals of a possible name confusion between the antidepressant Brintellix (vortioxetine) and the anti-blood clotting medication Brilinta (ticagrelor). According to the agency, the confusion between the names of the two drugs has resulted in incorrect prescribing and dispensing of medication, although there are no indications that patients have ingested the wrong drug.

The FDA recommends that health care professionals use the generic name of the medication in addition to the brand name when prescribing one of these medications. Read the announcement.

Keywords: Adenosine, Antidepressive Agents, Blood Coagulation, Pharmaceutical Preparations, Piperazines, Sulfides, United States Food and Drug Administration, Purinergic P2Y Receptor Antagonists

< Back to Listings